BACKGROUND: Peripheral arterial disease increases cardiovascular risk in many patient populations. The risks associated with an abnormal ankle-brachial index (ABI) in patients with type 2 diabetes and stable coronary artery disease have not been well described with respect to thresholds and types of cardiovascular events. METHODS: We examined 2,368 patients in the BARI 2D trial who underwent ABI assessment at baseline. Death and major cardiovascular events (death, myocardial infarction and stroke) during follow-up (average 4.3 years) were assessed across the ABI spectrum and by categorized ABI: low (≤0.90), normal (0.91-1.3), high (>1.3), or noncompressible. RESULTS: A total of 12,568 person-years were available for mortality analysis. During follow-up, 316 patients died, and 549 had major cardiovascular events. After adjustment for potential confounders, with normal ABI as the referent group, a low ABI conferred an increased risk of death (relative risk [RR] 1.6, CI 1.2-2.2, P = .0005) and major cardiovascular events (RR 1.4, CI 1.1-1.7, P = .004). Patients with a high ABI had similar outcomes as patients with a normal ABI, but risk again increased in patients with a noncompressible ABI with a risk of death (RR 1.9, CI 1.3-2.8, P = .001) and major cardiovascular event (RR 1.5, CI 1.1-2.1, P = .01). CONCLUSIONS: In patients with coronary artery disease and type 2 diabetes, ABI screening and identification of ABI abnormalities including a low ABI (<1.0) or noncompressible artery provide incremental prognostic information.
BACKGROUND: Peripheral arterial disease increases cardiovascular risk in many patient populations. The risks associated with an abnormal ankle-brachial index (ABI) in patients with type 2 diabetes and stable coronary artery disease have not been well described with respect to thresholds and types of cardiovascular events. METHODS: We examined 2,368 patients in the BARI 2D trial who underwent ABI assessment at baseline. Death and major cardiovascular events (death, myocardial infarction and stroke) during follow-up (average 4.3 years) were assessed across the ABI spectrum and by categorized ABI: low (≤0.90), normal (0.91-1.3), high (>1.3), or noncompressible. RESULTS: A total of 12,568 person-years were available for mortality analysis. During follow-up, 316 patients died, and 549 had major cardiovascular events. After adjustment for potential confounders, with normal ABI as the referent group, a low ABI conferred an increased risk of death (relative risk [RR] 1.6, CI 1.2-2.2, P = .0005) and major cardiovascular events (RR 1.4, CI 1.1-1.7, P = .004). Patients with a high ABI had similar outcomes as patients with a normal ABI, but risk again increased in patients with a noncompressible ABI with a risk of death (RR 1.9, CI 1.3-2.8, P = .001) and major cardiovascular event (RR 1.5, CI 1.1-2.1, P = .01). CONCLUSIONS: In patients with coronary artery disease and type 2 diabetes, ABI screening and identification of ABI abnormalities including a low ABI (<1.0) or noncompressible artery provide incremental prognostic information.
Authors: Jose M Mostaza; Luis Manzano; Carmen Suarez; Cristina Fernandez; Maria M García de Enterría; Raimundo Tirado; Francisco Nicolás; Miguel A Sanchez-Zamorano Journal: Atherosclerosis Date: 2010-10-28 Impact factor: 5.162
Authors: Kim Sutton-Tyrrell; Lakshmi Venkitachalam; Alka M Kanaya; Robert Boudreau; Tamara Harris; Trina Thompson; Rachel H Mackey; Marjolein Visser; Georgeta D Vaidean; Anne B Newman Journal: Stroke Date: 2008-02-07 Impact factor: 7.914
Authors: Maria Mori Brooks; Robert L Frye; Saul Genuth; Katherine M Detre; Richard Nesto; Burton E Sobel; Sheryl F Kelsey; Trevor J Orchard Journal: Am J Cardiol Date: 2006-04-17 Impact factor: 2.778
Authors: Deepak L Bhatt; Kim A Eagle; E Magnus Ohman; Alan T Hirsch; Shinya Goto; Elizabeth M Mahoney; Peter W F Wilson; Mark J Alberts; Ralph D'Agostino; Chiau-Suong Liau; Jean-Louis Mas; Joachim Röther; Sidney C Smith; Geneviève Salette; Charles F Contant; Joseph M Massaro; Ph Gabriel Steg Journal: JAMA Date: 2010-08-30 Impact factor: 56.272
Authors: F G R Fowkes; G D Murray; I Butcher; C L Heald; R J Lee; L E Chambless; A R Folsom; A T Hirsch; M Dramaix; G deBacker; J-C Wautrecht; M Kornitzer; A B Newman; M Cushman; K Sutton-Tyrrell; F G R Fowkes; A J Lee; J F Price; R B d'Agostino; J M Murabito; P E Norman; K Jamrozik; J D Curb; K H Masaki; B L Rodríguez; J M Dekker; L M Bouter; R J Heine; G Nijpels; C D A Stehouwer; L Ferrucci; M M McDermott; H E Stoffers; J D Hooi; J A Knottnerus; M Ogren; B Hedblad; J C Witteman; M M B Breteler; M G M Hunink; A Hofman; M H Criqui; R D Langer; A Fronek; W R Hiatt; R Hamman; H E Resnick; J Guralnik; M M McDermott Journal: JAMA Date: 2008-07-09 Impact factor: 56.272
Authors: Robert L Frye; Phyllis August; Maria Mori Brooks; Regina M Hardison; Sheryl F Kelsey; Joan M MacGregor; Trevor J Orchard; Bernard R Chaitman; Saul M Genuth; Suzanne H Goldberg; Mark A Hlatky; Teresa L Z Jones; Mark E Molitch; Richard W Nesto; Edward Y Sako; Burton E Sobel Journal: N Engl J Med Date: 2009-06-07 Impact factor: 91.245
Authors: Claudia R L Cardoso; Juliana V Melo; Guilherme C Salles; Nathalie C Leite; Gil F Salles Journal: Diabetologia Date: 2018-08-15 Impact factor: 10.122
Authors: Emilie H Zobel; Bernt Johan von Scholten; Henrik Reinhard; Frederik Persson; Tine W Hansen; Hans-Henrik Parving; Peter K Jacobsen; Peter Rossing Journal: Diabetologia Date: 2017-07-05 Impact factor: 10.122
Authors: Kamel Mohammedi; Mark Woodward; Yoichiro Hirakawa; Sophia Zoungas; Stephen Colagiuri; Pavel Hamet; Stephen Harrap; Neil Poulter; David R Matthews; Michel Marre; John Chalmers Journal: Cardiovasc Diabetol Date: 2016-09-02 Impact factor: 9.951
Authors: Claudia R L Cardoso; Juliana V Melo; Thainá R M Santos; Nathalie C Leite; Gil F Salles Journal: Cardiovasc Diabetol Date: 2021-02-27 Impact factor: 9.951
Authors: Vivianne L Jagt; Constantijn E V B Hazenberg; Jaap Kapelle; Maarten J Cramer; Frank L J Visseren; Jan Westerink Journal: PLoS One Date: 2022-03-10 Impact factor: 3.240